Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury

Poly(ADP-ribose) polymerase 1 (PARP1), as a potential target for the experimental therapy of acute lung injury (ALI), was identified over 20 years ago. However, clinical translation of this concept was not possible due to the lack of clinically useful PARP inhibitors. With the clinical introduction...

Full description

Saved in:

Bibliographic Details
Published in:	Cells (Basel, Switzerland) Vol. 11; no. 23; p. 3789
Main Authors:	Martins, Vanessa, Santos, Sidneia S, Rodrigues, Larissa de O C P, Salomao, Reinaldo, Liaudet, Lucas, Szabo, Csaba
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 26-11-2022 MDPI
Subjects:	Acute Lung Injury - drug therapy Animal models Animals Apoptosis Caspase-3 Cell culture cell death cytokines Disease Models, Animal DNA damage Dosage and administration Drug therapy Enzyme inhibitors Epithelial cells Extravasation Humans Inflammasomes Inflammation Inflammation Mediators - pharmacology Laboratory animals Lavage Lung Lung diseases Lungs Mice Monocytes Necrosis NF-κB protein olaparib Patient outcomes Poly(ADP-ribose) Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Ribose Switzerland United States > US Basel Switzerland cytokines cell death inflammation olaparib
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!